https://adagrasibinhibitor.com..../a-consensus-multi-v
In the context of anthracycline medications. Ma-Spore (MS) ALL trials welcomed three hundred sixty-nine children (1-9 years of age) with favorable-risk BCP-ALL, exhibiting no extramedullary disease or high-risk genetics, and having achieved minimal residual disease clearance (0.01%) after remission induction. Within the Malaysia-Singapore ALL 2003 study (MS2003), 167 patients categorized as standard-risk (SR), constituting 34% of the cohort, were treated using the MS
Мне нравится
Комментарий
Перепост
